CY1112326T1 - Παραγωγα της 6-(πυριδινυλ)-4-πυριμιδονης ως αναστολεις της κινασης 1 tau πρωτεϊνης - Google Patents

Παραγωγα της 6-(πυριδινυλ)-4-πυριμιδονης ως αναστολεις της κινασης 1 tau πρωτεϊνης

Info

Publication number
CY1112326T1
CY1112326T1 CY20111100427T CY111100427T CY1112326T1 CY 1112326 T1 CY1112326 T1 CY 1112326T1 CY 20111100427 T CY20111100427 T CY 20111100427T CY 111100427 T CY111100427 T CY 111100427T CY 1112326 T1 CY1112326 T1 CY 1112326T1
Authority
CY
Cyprus
Prior art keywords
tau protein
pyrimidone
pyridinyl
inhibitors
derivatives
Prior art date
Application number
CY20111100427T
Other languages
English (en)
Inventor
Kazutoshi Watanabe
Kenji Fukunaga
Toshiyuki Kohara
Fumiaki Uehara
Shinsuke Hiki
Satoshi Yokoshima
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Publication of CY1112326T1 publication Critical patent/CY1112326T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Μια ένωση που αναπαριστάται από τον τύπο (I), ένα οπτικά δραστικό ισομερές της ή ένα φαρμακευτικά αποδεκτό άλας αυτής: όπου το R1 αναπαριστά ένα C1-C12 αλκύλιο• το R2 αναπαριστά ένα άτομο υδρογόνου ή παρόμοιο• το R3 αναπαριστά ένα αλογόνο ή παρόμοιο• το q αναπαριστά έναν ακέραιο από 1 έως 7• το R4 αναπαριστά ένα αλογόνο ή παρόμοιο• το p αναπαριστά 0 ή έναν ακέραιο από 1 έως 5• το R5 αναπαριστά ένα C6-C10 αρύλιο, μια ετεροκυκλική ομάδα ή παρόμοια• και το Χ αναπαριστά οξυγόνο, ΝΗ ή παρόμοια, που χρησιμοποιείται για την προληπτική και/ή θεραπευτική αντιμετώπιση μιας νόσου, η οποία προκαλείται από την υπερδραστηριότητα της κινάσης 1 της tau πρωτεΐνης, όπως οι νευροεκφυλιστικές νόσοι (π.χ. νόσος του Αλτσχάιμερ).
CY20111100427T 2004-09-29 2011-05-04 Παραγωγα της 6-(πυριδινυλ)-4-πυριμιδονης ως αναστολεις της κινασης 1 tau πρωτεϊνης CY1112326T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004313115 2004-09-29
EP05790292A EP1805164B9 (en) 2004-09-29 2005-09-29 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors

Publications (1)

Publication Number Publication Date
CY1112326T1 true CY1112326T1 (el) 2015-12-09

Family

ID=35848411

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100427T CY1112326T1 (el) 2004-09-29 2011-05-04 Παραγωγα της 6-(πυριδινυλ)-4-πυριμιδονης ως αναστολεις της κινασης 1 tau πρωτεϊνης

Country Status (25)

Country Link
US (1) US8129377B2 (el)
EP (3) EP1805164B9 (el)
JP (1) JP5186213B2 (el)
KR (1) KR20070057931A (el)
CN (1) CN101048397A (el)
AR (1) AR051823A1 (el)
AT (1) ATE499356T1 (el)
AU (1) AU2005288045B2 (el)
BR (1) BRPI0515851A (el)
CA (1) CA2581179A1 (el)
CY (1) CY1112326T1 (el)
DE (1) DE602005026546D1 (el)
DK (1) DK1805164T3 (el)
EA (1) EA013004B1 (el)
ES (1) ES2359071T3 (el)
IL (1) IL182223A0 (el)
MX (1) MX2007003722A (el)
NO (1) NO20072214L (el)
NZ (1) NZ554722A (el)
PL (1) PL1805164T3 (el)
PT (1) PT1805164E (el)
SI (1) SI1805164T1 (el)
TW (1) TWI354669B (el)
WO (1) WO2006036015A2 (el)
ZA (1) ZA200703383B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AU2007287319A1 (en) * 2006-08-23 2008-02-28 Pfizer Products Inc. Pyrimidone compounds as GSK-3 inhibitors
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
ES2442926T3 (es) 2007-08-22 2014-02-14 Astrazeneca Ab Derivados de ciclopropilamida `978
BRPI0816705A2 (pt) 2007-09-14 2015-03-17 Mitsubishi Tanabe Pharma Corp Derivatido de 6-pirimidinil-pirimid-2-ona
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9006232B2 (en) 2009-08-13 2015-04-14 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives
WO2011062194A1 (ja) 2009-11-18 2011-05-26 武田薬品工業株式会社 アミノピリジン誘導体
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
MX336333B (es) 2010-02-18 2016-01-15 Astrazeneca Ab Nueva forma cristalina de un derivado de ciclopropilbenzamida.
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
ES2926255T3 (es) 2017-04-24 2022-10-24 Tesaro Inc Métodos de fabricación de niraparib
CN117143079A (zh) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) * 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
EP1136483A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
DK1427709T3 (da) 2001-09-21 2006-04-03 Mitsubishi Pharma Corp 3-substituerede 4-pyrimidonderivater
JP4347050B2 (ja) * 2001-09-21 2009-10-21 田辺三菱製薬株式会社 3−置換−4−ピリミドン誘導体
EP1454908B1 (en) * 2003-03-07 2008-02-27 Sanofi-Aventis Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
DE602005026546D1 (de) 2011-04-07
US20090239864A1 (en) 2009-09-24
ES2359071T3 (es) 2011-05-18
AU2005288045B2 (en) 2011-08-18
TWI354669B (en) 2011-12-21
AR051823A1 (es) 2007-02-14
JP5186213B2 (ja) 2013-04-17
JP2008514587A (ja) 2008-05-08
KR20070057931A (ko) 2007-06-07
CA2581179A1 (en) 2006-04-06
EP2261224A2 (en) 2010-12-15
EP2266969A3 (en) 2011-02-16
WO2006036015A2 (en) 2006-04-06
AU2005288045A1 (en) 2006-04-06
EP1805164B1 (en) 2011-02-23
NZ554722A (en) 2010-07-30
WO2006036015A3 (en) 2006-06-01
EA013004B1 (ru) 2010-02-26
EP1805164A2 (en) 2007-07-11
ZA200703383B (en) 2009-05-27
PL1805164T3 (pl) 2011-07-29
MX2007003722A (es) 2007-05-23
AU2005288045A2 (en) 2008-05-29
EP2266969A2 (en) 2010-12-29
TW200626573A (en) 2006-08-01
EP1805164B9 (en) 2011-09-07
EA200700756A1 (ru) 2007-10-26
ATE499356T1 (de) 2011-03-15
NO20072214L (no) 2007-06-12
US8129377B2 (en) 2012-03-06
SI1805164T1 (sl) 2011-05-31
IL182223A0 (en) 2007-09-20
DK1805164T3 (da) 2011-05-16
BRPI0515851A (pt) 2008-08-12
PT1805164E (pt) 2011-04-11
EP2261224A3 (en) 2011-02-16
CN101048397A (zh) 2007-10-03

Similar Documents

Publication Publication Date Title
CY1112326T1 (el) Παραγωγα της 6-(πυριδινυλ)-4-πυριμιδονης ως αναστολεις της κινασης 1 tau πρωτεϊνης
TW200621760A (en) 2-morpholino-4-pyrimidone compound
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
EA200970598A1 (ru) Замещенные производные гетероарилпиридопиримидона
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
EA200870384A1 (ru) 3,7-диамино-10h-фенотиазиновые соли и их применение
NO20083207L (no) Inhibitorer av IAP
EA200601584A1 (ru) Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
DE602006009968D1 (de) N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
MY156747A (en) Isoxazolo-pyridine derivatives
NO20060768L (no) 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser
NO20070606L (no) Inhibitorer av IAP
RS28004A (en) Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EA200501315A1 (ru) 8-ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА
TW200505922A (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
ATE523199T1 (de) Pyridazinverbindungen und verfahren
EA200970555A1 (ru) Трициклическое соединение и его медицинское применение
EA200702199A1 (ru) Новые соединения для лечения воспалительных заболеваний
NO20073330L (no) Sulfanylsubstituerte fenylmetanoner som glycintransportor 1 (glyt-1) inhibitorer for behandling av nevrologiske og nevropsykiatriske forstyrrelser